director of preclinical studies
SANDRO ALVES, PhD, 12 year-expertise in research for neurodegenerative disorders and gene therapy, is director of preclinical studies at Brainvectis. Sandro leads the Brainvectis Preclinical Research Office and directs the preclinical activity on Alzheimer’s disease and Huntington’s disease. He is also involved in the scientific consideration of future therapeutic strategies to be developed in other neurodegenerative disorders. Prior to joining Brainvectis, Sandro conducted his research at the Brain and Spine Institute (Paris), evaluating therapeutic strategies in animal models of Spinocerebellar ataxia and then at MIRCen/CEA, developing therapeutic research in animal models of Alzheimer’s and Huntington’s disease. Sandro obtained his PhD in Health Sciences and Technology (Neuroscience) from the Center for Neuroscience and the Faculty of Pharmacy of the University of Coimbra (Portugal), in 2008, where he developed gene therapy correction in animal models of Machado-Joseph disease.
gene therapy correction in animal models of Machado-Joseph disease.